jCyte update
In spring 2021, the US company jCyte announced detailed results from their successful phase 2b clinical trial of jCell, a stem cell-based treatment for RP.
Search
Search results
New Gene Insertion Therapy for Stargard Disease in Development
SalioGen Developing Novel Gene Insertion Therapy for Stargardt disease.
Retina UK’s Souper Tuesday
Be a souper-star and raise funds whilst having lunch for #TeamRetinaUK
Meet our Trustee: Lynda Cantor MBE, Hon President
Lynda Cantor was a founder member of the charity in 1975 and one of our original trustees
E-Newsletter Sept 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.
A new approach to treating inherited sight loss
A new approach to treating inherited sight loss
From isolation to exploration: what you can do to build your confidence when travelling
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Fundraising FAQs
Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.
Encouraging results from ProQR USH2A clinical trial
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.
Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.